A new era? Biocon is stepping into India's generic GLP‑1 market, aiming for affordable diabetes and weight‑loss solutions. CEO Tambe reports strong earnings growth, hinting at a future shift in metabolic care. What does this mean for patients?
A new era? Biocon is stepping into India's generic GLP‑1 market, aiming for affordable diabetes and weight‑loss solutions. CEO Tambe reports strong earnings growth, hinting at a future shift in metabolic care. What does this mean for patients?
GST Discussion and Probable Stock Impact.
Must watch:
https://youtube.com/shorts/_tEJv0Mseb0?si=Towb_5wr2eTYaI7S
#NewsUpdate #financenews #FinanceMinistry #gstcouncil #sharemarket #stockmarket #nifty #sensex #nse #bse #taxes #Biocon #DRREDDY #UltraTechCement #hindustanaeronauticslimited #BDL